Skip to main content
. 2020 Dec 29;11:594087. doi: 10.3389/fphar.2020.594087

FIGURE 4.

FIGURE 4

Level of VEGF-A in AH from nAMD patients with normal response (N), incomplete response (R), and controls (C). The VEGF-A was assessed by multiplex (A) or AlphaLISA (B) assays, and the results expressed are dependent on the anti-VEGF treatment (aflibercept [Aflib] or ranibizumab [Ranib]). **p < 0.0003 and #p < 0.0001.